title: Lymphoproliferative response to synthetic V3 loop P18 peptide and HIV-1 envelope glycoprotein among individuals immunized with gp160 candidate vaccines.
abstract: Because T-cell responses are critical for defense against viral infections, the synthetic P18 peptide (RIQRGPGRAFVTIGK) and active component of gp160 protein has previously been shown to induce cytotoxic and helper T-lymphocyte responses. In order to further define the T-helper cells, responses which are known to play a role in enhancing the immunological response to foreign antigen, we studied the response of individuals immunized with HIV gp160 candidate vaccines. We investigated the proliferative cellular response of peripheral blood mononuclear cells (PBMC) derived from individuals immunized with gp160 antigens in three different protocols. We found a PBMC proliferative response to synthetic P18 peptide in healthy immunized individuals induced by gp160 antigen with or without vaccinia virus. There was correlation between the proliferative response to P18 peptide and other antigens such as HIV-like proteins and gp160 molecule. HLA-DR typing revealed the possible presentation of P18 peptide by several different class II molecules. Since these class II molecules occur frequently in the general population, P18 peptide appears to contain broadly reactive epitopes and thus is presented by multiple HLA class II molecules. Due to its broad reactivity P18 peptide is one of the candidates for inclusion as a subunit vaccine against HIV-1.
authors.affiliation: Université Pierre et Marie Curie, Paris, France.
authors.forename: Z
authors.initials: Z
authors.lastname: Moukrim
authors.forename: Y Y
authors.initials: YY
authors.lastname: Cho
authors.forename: J P
authors.initials: JP
authors.lastname: Mbika
authors.forename: A
authors.initials: A
authors.lastname: Achour
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology* / Q000627:therapeutic use; D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D000328:Adult; D000939:Epitopes / Q000276:immunology; D005260:Female; D005802:Genes, MHC Class II / Q000276:immunology; D019302:HIV Envelope Protein gp160 / Q000276:immunology* / Q000494:pharmacology; D015497:HIV-1; D015989:Healthy Worker Effect; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000494:pharmacology*; D014614:Vaccines, Synthetic / Q000276:immunology / Q000627:therapeutic use; D014838:Volunteers
chemical_list: D016915:AIDS Vaccines; D000939:Epitopes; D019302:HIV Envelope Protein gp160; D010446:Peptide Fragments; D014614:Vaccines, Synthetic